Sponsor

Stelexis Biosciences Inc.

United States 345 Park Avenue South Floor 12th, 10010-1707, United States

About the sponsor

Stelexis Biosciences Inc. is focused on relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes, with clinical interest centered on difficult-to-treat blood cancers that have limited treatment options after prior therapy.

Relapsed/refractory AML
Higher-risk MDS
Hematologic malignancies

The sponsor’s research activity in this area reflects a therapeutic emphasis on oncology, particularly hematologic oncology and treatment-resistant disease.

About Specializations

Stelexis Biosciences Inc. runs clinical trials in conditions such as Acute myeloid leukaemia refractory, Acute myeloid leukaemia recurrent, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

1 clinical trial

Acute myeloid leukaemia refractory+1

Recruiting

Study on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

Registered drugNo placebo